26 Beaumont Street
About Oxford BiodynamicsOBD was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases.
CEO: Christian Hoyer Millar
CSO: Alexandre Akoulitchev
CTO: Aroul Ramadass
CFO: Katie Long
7 articles with Oxford Biodynamics
Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19
Highly diverse samples will enable development of world’s first 3D genomics prognostic immune health test for disease severity
10/29/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University
Expertly annotated patient samples from world-class clinical research facility Samples used to advance development of the world’s first 3D genomic severity test for COVID-19 disease built using the EpiSwitch™ platform Goal is to provide insight into a wide range of COVID-19 responses, from mild to severe Adds to Oxford BioDynamics’ growing bank of 500+ procured samples from cohorts around the world
Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, today announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at The Society for Immunotherapy of Cancer's 34th Annual Meeting.
Proprietary Technology Platform to Assess Biomarker Panels in People with ALS
Oxford Biodynamics Presents Applications Of Its Epigenetic Biomarker Technology EpiSwitch At The Annual Meeting Of The American Society of Hematology In San Diego